Please assess the completion status of the following clinical trial:

Trial Title: Caelyx as Primary Treatment for Patients With Breast Cancer and a History of Heart Disease and/or Age Over 65 Years

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed invasive breast cancer (tumor \> 2 cm).~* Estrogen receptor-negative or -weakly positive tumors (less than 50% of cells), as evaluated using IHC.~* Risk factors for developing anthracycline-induced cardiomyopathy.~Exclusion Criteria:~* Severe heart failure (NYHA Class III or IV) .~* Metastatic disease.~* LVEF \< 45%.~* Pregnant or breast-feeding patients.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Primary chemotherapy regimen consisting of four cycles of pegylated-liposomal doxorubicine at 35 mg/m² IV plus CPM 600 mg/m² on Day 1 every 4 weeks followed by paclitaxel 80 mg/m²/week for 12 weeks before surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).